These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1060 related articles for article (PubMed ID: 30577723)

  • 1. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
    Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
    Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma.
    Xu RC; Liu HC; Li JL; Li K; Ou SY; Yu ZY; Kong Y; Ma GA; Shao WS
    Curr Med Res Opin; 2015 Aug; 31(8):1553-60. PubMed ID: 26067770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
    Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
    AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria.
    Takuma Y; Takabatake H; Morimoto Y; Toshikuni N; Kayahara T; Makino Y; Yamamoto H
    Radiology; 2013 Dec; 269(3):927-37. PubMed ID: 24086071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation and/or Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.
    Orimo T; Kamiyama T; Yokoo H; Wakayama K; Shimada S; Einama T; Kamachi H; Taketomi A
    Dig Surg; 2018; 35(5):427-434. PubMed ID: 28903105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas.
    Zuo TY; Liu FY; Wang MQ; Chen XX
    Chin Med J (Engl); 2017 Nov; 130(22):2666-2673. PubMed ID: 29133753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome.
    Liu W; Xu H; Ying X; Zhang D; Lai L; Wang L; Tu J; Ji J
    Med Sci Monit; 2020 Jul; 26():e923263. PubMed ID: 32667906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.
    Huang K; Qian T; Chen W; Lao M; Li H; Lin WC; Chen BW; Bai X; Gao S; Ma T; Liang T
    BMC Cancer; 2024 May; 24(1):620. PubMed ID: 38773564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis.
    Kim GH; Kim JH; Shim JH; Kim SY; Kim PH; Ko HK; Gwon DI; Shin JH; Lee SJ; Chu HH; Won HJ; Shin YM; Kim N
    Eur Radiol; 2024 Sep; 34(9):5517-5528. PubMed ID: 38329504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.
    Yuan P; Wang F; Zhu G; Chen B
    Invest New Drugs; 2021 Oct; 39(5):1383-1388. PubMed ID: 33754235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma.
    Nouso K; Kariyama K; Nakamura S; Oonishi A; Wakuta A; Oyama A; Ako S; Dohi C; Wada N; Morimoto Y; Takeuchi Y; Kuwaki K; Onishi H; Ikeda F; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2017 Mar; 32(3):695-700. PubMed ID: 27597181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma.
    Yuan P; Zhang Z; Kuai J
    J BUON; 2019; 24(1):163-170. PubMed ID: 30941966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.